1. SILK studies — capturing the turnover of proteins linked to neurodegenerative diseases
- Author
-
Randall J. Bateman, Nicolas R. Barthélemy, Audrey Gabelle, Tim West, Henrik Zetterberg, Kevin E. Yarasheski, Bruce W. Patterson, Selina Wray, Nick C. Fox, Jonathan D. Rohrer, Donald L. Elbert, Timothy M. Miller, Norelle C. Wildburger, Sylvain Lehmann, Claire A Leckey, Chihiro Sato, Jonathan M. Schott, Brendan P. Lucey, Christophe Hirtz, Ross W. Paterson, Celeste M. Karch, Département de neurologie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), University College of London [London] (UCL), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Dementia Research Centre [London] (DRC), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institute of Research in Biotherapy, Laboratory of Biochemistry and Clinical Proteomics, Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Institut de génétique humaine (IGH), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Department of Bioengineering Sciences, Nagoya University, Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Department of Mathematics and Statistics [Canada], Dalhousie University [Halifax], Institute of Neurology [London], UCL, Institute of Neurology [London], Hôpital Gui de Chauliac [Montpellier]-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), and Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
- Subjects
0301 basic medicine ,[SDV]Life Sciences [q-bio] ,SOD1 ,tau Proteins ,[SDV.BC]Life Sciences [q-bio]/Cellular Biology ,Article ,Superoxide dismutase ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,In vivo ,Protein biosynthesis ,Humans ,Medicine ,ComputingMilieux_MISCELLANEOUS ,Neuroinflammation ,chemistry.chemical_classification ,Amyloid beta-Peptides ,biology ,business.industry ,Brain ,Neurodegenerative Diseases ,medicine.disease ,In vitro ,3. Good health ,Amino acid ,030104 developmental biology ,chemistry ,Biochemistry ,Isotope Labeling ,biology.protein ,Neurology (clinical) ,Alzheimer's disease ,business ,030217 neurology & neurosurgery - Abstract
Alzheimer disease (AD) is one of several neurodegenerative diseases characterized by dysregulation, misfolding and accumulation of specific proteins in the CNS. The stable isotope labelling kinetics (SILK) technique is based on generating amino acids labelled with naturally occurring stable (that is, nonradioactive) isotopes of carbon and/or nitrogen. These labelled amino acids can then be incorporated into proteins, enabling rates of protein production and clearance to be determined in vivo and in vitro without the use of radioactive or chemical labels. Over the past decade, SILK studies have been used to determine the turnover of key pathogenic proteins amyloid-β (Aβ), tau and superoxide dismutase 1 (SOD1) in the cerebrospinal fluid of healthy individuals, patients with AD and those with other neurodegenerative diseases. These studies led to the identification of several factors that alter the production and/or clearance of these proteins, including age, sleep and disease-causing genetic mutations. SILK studies have also been used to measure Aβ turnover in blood and within brain tissue. SILK studies offer the potential to elucidate the mechanisms underlying various neurodegenerative disease mechanisms, including neuroinflammation and synaptic dysfunction, and to demonstrate target engagement of novel disease-modifying therapies.
- Published
- 2019